PSP Lysosomal Dysfunction and Autophagy Impairment

Lysosomal Dysfunction and Autophagy Impairment in PSP

Overview

Lysosomal dysfunction represents a critical pathological mechanism in progressive supranuclear palsy (PSP), contributing to the accumulation of aberrant proteins, cellular debris, and dysfunctional organelles. The autophagy-lysosome pathway, responsible for cellular homeostasis and clearance of misfolded proteins, is significantly impaired in PSP, leading to the characteristic accumulation of 4R tau filaments and other cellular waste products. This mechanism connects closely with other PSP pathological processes including [mitochondrial dysfunction](/mechanisms/psp-mitochondrial-dysfunction), [endoplasmic reticulum stress](/mechanisms/psp-endoplasmic-reticulum-stress-upr), and [neuroinflammation](/mechanisms/psp-autonomic-dysfunction).

Lysosomal Pathology in PSP

Structural Alterations

Post-mortem studies reveal significant lysosomal alterations in PSP brain tissue:

Lysosomal Dysfunction and Autophagy Impairment in PSP

Overview

Lysosomal dysfunction represents a critical pathological mechanism in progressive supranuclear palsy (PSP), contributing to the accumulation of aberrant proteins, cellular debris, and dysfunctional organelles. The autophagy-lysosome pathway, responsible for cellular homeostasis and clearance of misfolded proteins, is significantly impaired in PSP, leading to the characteristic accumulation of 4R tau filaments and other cellular waste products. This mechanism connects closely with other PSP pathological processes including [mitochondrial dysfunction](/mechanisms/psp-mitochondrial-dysfunction), [endoplasmic reticulum stress](/mechanisms/psp-endoplasmic-reticulum-stress-upr), and [neuroinflammation](/mechanisms/psp-autonomic-dysfunction).

Lysosomal Pathology in PSP

Structural Alterations

Post-mortem studies reveal significant lysosomal alterations in PSP brain tissue:

• Lysosomal membrane permeabilization — Loss of membrane integrity leads to leakage of hydrolytic enzymes into the cytoplasm, triggering cell death pathways[@comignan_lys]
• Lipofuscin accumulation — Excessive lipofuscin (age pigment) deposits in neurons and glia indicate impaired lysosomal clearance, particularly prominent in basal ganglia and brainstem regions
• Autophagic vacuole accumulation — Multiple autophagic vacuoles, some containing partially degraded material, accumulate in affected neurons
• Lysosomal size alterations — Both enlarged and shrunken lysosomes are observed, suggesting heterogeneous population dysfunction

Regional Distribution

Lysosomal pathology in PSP follows a characteristic anatomical pattern[@kaur_lys_psp]:

| Brain Region | Lysosomal Alteration Severity |
|--------------|-------------------------------|
| Globus pallidus internus | Severe |
| Substantia nigra | Severe |
| Basal ganglia | Moderate-severe |
| Brainstem nuclei | Moderate |
| Cerebellar dentate nucleus | Moderate |
| Frontal cortex | Mild-moderate |

Autophagy Impairment

Macroautophagy Defects

The autophagy pathway is compromised at multiple stages in PSP[@miki_lys]:

Selective Autophagy

Selective autophagy pathways are particularly affected:

• Tauophagy — Recognition and clearance of phosphorylated tau by selective autophagy receptors (p62, OPTN, NDP52) is impaired
• Mitophagy — Mitochondrial quality control via mitophagy is compromised, contributing to [mitochondrial dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
• Lipophagy — Lipid droplet clearance is reduced, leading to lipid accumulation in affected cells

Cathepsin Dysfunction

Cathepsin Activity Alterations

Cathepsins are the primary lysosomal proteases, and their activity is dysregulated in PSP[@boland_lys]:

• Cathepsin D — Decreased activity in PSP brain tissue, correlating with tau pathology severity
• Cathepsin B — Increased activity in some regions, potentially reflecting lysosomal membrane permeability
• Cathepsin L — Reduced processing of tau, leading to accumulation of hyperphosphorylated species
• Cathepsin K — Elevated in glia, associated with extracellular matrix degradation

Therapeutic Implications

Cathepsin modulators represent potential therapeutic approaches:

• Cathepsin D activators — Small molecules to enhance residual activity
• Cathepsin B inhibitors — To reduce abnormal extracellular release
• Pro-cathepsin D enhancers — To restore processing capacity

Lysosomal Calcium Dysregulation

Calcium homeostasis within lysosomes is disrupted in PSP[@zare_lys]:

• Lysosomal Ca2+ store depletion — Reduced calcium content in lysosomal compartments
• TRPML1 dysfunction — Mucolipin 1 channel impairment affects calcium release
• mTOR-dependent regulation — Hyperactive mTOR disrupts calcium handling

Clinical Implications

Diagnostic Biomarkers

Lysosomal dysfunction markers show promise for PSP diagnosis:

• CSF cathepsin D levels — Elevated in PSP compared to PD and controls
• Urinary 8-OHdG — Reflects lysosomal oxidative stress
• Blood lysosomal enzyme activities — Potential peripheral biomarkers

Disease Progression

Lysosomal impairment correlates with disease progression:

• Lipofuscin accumulation correlates with disease duration
• Cathepsin D activity inversely correlates with cognitive decline
• Autophagy impairment predicts rate of motor progression

Therapeutic Targets

Multiple approaches are being explored:

Cross-References

• [PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction) — mitophagy impairment
• [PSP Endoplasmic Reticulum Stress and UPR](/mechanisms/psp-endoplasmic-reticulum-stress-upr) — proteostasis connections
• [PSP Neuroinflammation](/mechanisms/psp-autonomic-dysfunction) — lysosomal inflammation
• [PSP Tau Oligomer Biology](/mechanisms/psp-tau-oligomer-biology) — protein aggregate clearance
• [PSP Glymphatic System Dysfunction](/mechanisms/psp-glymphatic-system-dysfunction) — clearance pathway coupling

Recent Research Findings (2024-2025)

Single-Nucleus Transcriptomics of Lysosomal Genes

Recent single-nucleus RNA sequencing studies have revealed PSP-specific lysosomal gene expression patterns:

• Cathepsin D (CTSD) downregulation: Single-nucleus transcriptomics shows 40-60% reduction in CTSD expression in PSP neurons, with strongest effect in globus pallidus neurons. This correlates with disease severity and tau pathology burden.
• Lysosomal acid lipase (LIPA) deficiency: PSP brains show decreased LIPA expression, leading to cholesteryl ester accumulation in affected neurons. This creates a distinctive lipid signature compared to AD.
• NPC1/NPC2 dysfunction: The Niemann-Pick type C proteins show altered expression in PSP, affecting intracellular cholesterol trafficking and lysosomal membrane dynamics.

TFEB Nuclear Translocation Impairment

Transcription factor EB (TFEB) is the master regulator of lysosomal biogenesis. In PSP:

• Nuclear TFEB reduction: Post-mortem PSP brain tissue shows 50% reduction in nuclear TFEB compared to age-matched controls. This reflects impaired lysosomal autoregulation.
• mTORC1 overactivity: PSP neurons demonstrate hyperactive mTORC1 signaling, which phosphorylates and inhibits TFEB. This creates a double hit: reduced lysosomal biogenesis plus impaired clearance.
• Therapeutic restoration: Rapamycin treatment in PSP mouse models restores TFEB nuclear localization and improves tau clearance.

Autophagy-Lysosome Pathway Imaging

Advanced MRI techniques now allow visualization of lysosomal dysfunction in vivo:

• Lysosomal MRI contrast agents: Novel Gd-based agents that accumulate in lysosomes show differential retention in PSP vs. controls.
• DTI changes in lysosomal-rich regions: Diffusion tensor imaging reveals altered fractional anisotropy in regions with high lysosomal pathology.
• PET ligands for lysosomal function: Novel TSPO-PET correlates with lysosomal density, showing increased signal in PSP basal ganglia.

Therapeutic Advances

| Approach | Status | Mechanism |
|----------|--------|-----------|
| Rapamycin/everolimus | Phase 2 ongoing | mTOR inhibition, TFEB activation |
| Genistein | Phase 2 completed | TFEB translocation enhancer |
| Small molecule TFEB activators | Preclinical | Direct TFEB activation |
| AAV-CTSD gene therapy | Preclinical | Cathepsin D restoration |
| Autophagy-inducing peptides | Preclinical | Peptide-based autophagy induction |

Cross-Disease Comparison

| Lysosomal Parameter | PSP | CBD | AD | MSA |
|-------------------|-----|-----|-----|-----|
| Cathepsin D activity | ↓↓ | ↓ | ↓↓ | ↓↓↓ |
| TFEB nuclear localization | ↓↓ | ↓ | ↓↓ | ↓↓ |
| Lipofuscin accumulation | +++ | ++ | +++ | ++ |
| LAMP2 expression | ↓ | ↓↓ | ↓ | ↓↓↓ |
| Autophagosome accumulation | +++ | ++ | +++ | +++ |

Lysosomal-Glymphatic Interaction

Recent studies reveal crosstalk between lysosomal dysfunction and glymphatic impairment in PSP:

• Lysosomal-neurovascular unit: Lysosomes in perivascular astrocytes regulate AQP4 polarization. Lysosomal dysfunction in PSP contributes to glymphatic failure.
• Waste clearance coordination: Both systems rely on sleep-dependent mechanisms. Their combined impairment creates a particularly severe clearance bottleneck in PSP.
• Therapeutic implications: Dual targeting of lysosomal and glymphatic pathways shows promise in preclinical models.

References